Takeda to Discontinue GAMMAGARD S/D by End of 2027, Raising Concerns Over European Immunoglobulin Supply
Takeda Pharmaceutical has confirmed the planned discontinuation of GAMMAGARD S/D, its intravenous immunoglobulin (IVIG) product, at the end of December 2027. While existing inventory will remain available until depleted, the move raises significant questions for European healthcare systems that depend on immunoglobulin therapies for patients with rare immune disorders. Supply chain planners and patient advocacy groups across Europe are urged to begin contingency planning now.
ViaNews Editorial Team (Europe)•